Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06249048 · ClinicalTrials.gov registry record · Phase 1

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

A Phase 1 study of Advanced Solid Tumor, sponsored by Strand Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
108
Enrollment target
7
Study locations

NCT06249048 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Strand Therapeutics. The registered enrollment target is 108 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (44% lower). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06249048, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Strand Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
108 participants
Enrollment target
7
Study locations

Study Summary

Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. The study now includes a monotherapy cohort targeting visceral lesions and a separate Phase 2 monotherapy cohort for advanced melanoma.

Conditions Studied

Advanced Solid Tumor

Interventions

  • BIOLOGICAL STX-001
  • BIOLOGICAL Keytruda®

Study Locations (7)

Arizona

  • HonorHealth Research and Innovation Institute - Scottsdale

California

  • NextGen Oncology - Beverly Hills

Ohio

  • Cleveland Clinic - Cleveland

Pennsylvania

  • University of Pittsburgh Medical Center - Pittsburgh

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Utah

  • Huntsman Cancer Institute - University of Utah - Salt Lake City

Other

  • Melanoma Institute Australia - Wollstonecraft

Trial Details

FieldValue
Enrollment Target 108 participants
Start Date 2024-05-03
Est. Completion 2028-11
Phase Phase 1

Sponsor

Strand Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06249048

The ClinicalTrials.gov registry entry for NCT06249048 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (44% lower). The listed sponsor is Strand Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which STX-001 is the first listed.

NCT06249048 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arizona, California, Ohio.

Frequently Asked Questions

What is clinical trial NCT06249048 about?

NCT06249048 is a clinical study titled "Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab". Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. The study now...

What is the current status of trial NCT06249048?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2024-05-03. Estimated completion is 2028-11.

What conditions does trial NCT06249048 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06249048?

The interventions under investigation include: STX-001 (BIOLOGICAL), Keytruda® (BIOLOGICAL).

Who is sponsoring clinical trial NCT06249048?

This trial is sponsored by Strand Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06249048 being conducted?

This trial has 7 study locations across Arizona, California, Ohio, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.